Evidence map›Paper›PMID 35275926›Full record

ArticlePloS one2022

Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes.

Sebastian Himbert, Isabella Passos Gastaldo, Rashik Ahmed, Karla Martinez Pomier, Braeden Cowbrough, Dushyant Jahagirdar, Samantha Ros, Janos Juhasz, Harald D H Stöver, Joaquin Ortega and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. SARS-CoV-2 virus-like-particlesNanoscale advances · 2023
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Sebastian HimbertDepartment of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
Isabella Passos GastaldoDepartment of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
Rashik AhmedDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Karla Martinez PomierDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Braeden CowbroughDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Dushyant JahagirdarDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada.
Samantha RosDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Janos JuhaszDepartment of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.
Harald D H StöverDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Joaquin OrtegaDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada.
Giuseppe MelaciniDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Dawn M E BowdishDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Maikel C RheinstädterDepartment of Physics and Astronomy, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-0558-7475
McMaster University · CAMcGill University · CAJuravinski Cancer Centre · CASt. Joseph’s Healthcare Hamilton · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapeutic strategies are needed to control the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic. Here, we present a protocol to anchor the SARS-CoV-2 spike (S-)protein in the cytoplasmic membranes of erythrocyte liposomes. A surfactant was used to stabilize the S-protein's structure in the aqueous environment before insertion and to facilitate reconstitution of the S-proteins in the erythrocyte membranes. The insertion process was studied using coarse grained Molecular Dynamics (MD) simulations. Liposome formation and S-protein anchoring was studied by dynamic light scattering (DLS), ELV-protein co-sedimentation assays, fluorescent microcopy and cryo-TEM. The Erythro-VLPs (erythrocyte based virus like particles) have a well defined size of ∼200 nm and an average protein density on the outer membrane of up to ∼300 proteins/μm2. The correct insertion and functional conformation of the S-proteins was verified by dose-dependent binding to ACE-2 (angiotensin converting enzyme 2) in biolayer interferometry (BLI) assays. Seroconversion was observed in a pilot mouse trial after 14 days when administered intravenously, based on enzyme-linked immunosorbent assays (ELISA). This red blood cell based platform can open novel possibilities for therapeutics for the coronavirus disease (COVID-19) including variants, and other viruses in the future.

Indexed as

COVID-19COVID-19 VaccinesErythrocyte MembraneMolecular Dynamics SimulationSpike Glycoprotein, CoronavirusVaccines, Virus-Like ParticleAnimalsFemaleLiposomesMicePilot ProjectsProtein DomainsSARS-CoV-2COVID-19 VaccinesLiposomesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Virus-Like Particle

Identifiers

PMID35275926
PMCPMC8916654
OpenAlexW4220960920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.